Rotavirus vs. Sucrose for Vaccine Injection Pain

NCT ID: NCT02174705

Last Updated: 2014-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized trial will compare the analgesic effectiveness of oral rotavirus vaccine to sugar water for reducing vaccine injection pain in infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccination Pain Management

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sucrose

Sucrose prior to vaccine injections

Group Type EXPERIMENTAL

Sucrose

Intervention Type DRUG

Sucrose 24% orally prior to vaccine injections

Rotavirus

Rotavirus prior to vaccine injections

Group Type ACTIVE_COMPARATOR

Rotavirus

Intervention Type DRUG

Rotavirus vaccine orally prior to vaccine injections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sucrose

Sucrose 24% orally prior to vaccine injections

Intervention Type DRUG

Rotavirus

Rotavirus vaccine orally prior to vaccine injections

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy infants receiving rotavirus vaccine in conjunction with primary immunizations in the first 6 months of life

Exclusion Criteria

* impaired neurological development, history of seizures, sedatives or narcotics in preceding 24 hours, parent unable to use study tools, prior participation in the trial
Minimum Eligible Age

2 Months

Maximum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Anna Taddio

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anna Taddio

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Taddio, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Toronto

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kindercare

Toronto, Ontario, Canada

Site Status RECRUITING

Anna Taddio

Toronto, Ontario, Canada

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anna Taddio, PhD

Role: CONTACT

416-978-8822

Moshe Ipp, MD

Role: CONTACT

416-924-7171

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dan Flanders, MD

Role: primary

(416) 848-7665

Anna Taddio, PhD

Role: backup

416-978-8822

Anna Taddio, PhD

Role: primary

416-978-8822

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

30427

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.